연구동향 분석
박사

Application of single cell mRNA-sequencing to suggest a personalized anticancer therapeutic strategy in bladder cancer

정다은 2018년

논문상세정보
인용/피인용
' Application of single cell mRNA-sequencing to suggest a personalized anticancer therapeutic strategy in bladder cancer' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Personalized anticancer therapeutic strategy
  • Single cell mRNA sequencing
  • Tumor microenvironment
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
71 0

0.0%

' Application of single cell mRNA-sequencing to suggest a personalized anticancer therapeutic strategy in bladder cancer' 의 참고문헌

  • de Velasco, G., et al., Urothelial cancer proteomics provides both prognostic and functional information. Sci Rep, 2017. 7(1): p. 15819.
  • Zhu, L., et al., Cellular metabolism and macrophage functional polarization. Int Rev Immunol, 2015. 34(1): p. 82-100.
  • Zhao, S., et al., Midkine upregulates MICA/B expression in human gastric cancer cells and decreases natural killer cell cytotoxicity. Cancer Immunol Immunother, 2012. 61(10): p. 1745- 53.
  • Zhang, X. and Y. Zhang, Bladder Cancer and Genetic Mutations. Cell Biochem Biophys, 2015. 73(1): p. 65-9.
  • Zhang, Q.W., et al., Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One, 2012. 7(12): p. e50946.
  • Zhang, F., et al., TGF-beta induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype. Oncotarget, 2016. 7(32): p. 52294-52306.
  • Zhang, D., et al., Midkine derived from cancer-associated fibroblasts promotes cisplatinresistance via up-regulation of the expression of lncRNA ANRIL in tumour cells. Sci Rep, 2017. 7(1): p. 16231.
  • Yu, M., et al., RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature, 2012. 487(7408): p. 510-3.
  • Yap, T.A., et al., Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med, 2012. 4(127): p. 127ps10.
  • Yap, T.A., et al., Envisioning the future of early anticancer drug development. Nat Rev Cancer, 2010. 10(7): p. 514-23.
  • Yang, L. and Y. Zhang, Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol, 2017. 10(1): p. 58.
  • Xing, F., J. Saidou, and K. Watabe, Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed), 2010. 15: p. 166-79.
  • Wu, T. and Y. Dai, Tumor microenvironment and therapeutic response. Cancer Letters, 2017. 387: p. 61-68.
  • Whyte, D.B., et al., K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem, 1997. 272(22): p. 14459-64.
  • Wei, L., et al., Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts. Oncotarget, 2016. 7(47): p. 76374- 76389.
  • Wang, W., et al., Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res, 2009. 15(21): p. 6630-8.
  • Wang, P., et al., Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor. Urology, 2007. 69(4): p. 780-4.
  • Wang, M., et al., Role of tumor microenvironment in tumorigenesis. J Cancer, 2017. 8(5): p. 761-773.
  • Wang, B., et al., High CD204+ tumor-infiltrating macrophage density predicts a poor prognosis in patients with urothelial cell carcinoma of the bladder. Oncotarget, 2015. 6(24): p. 20204-14.
  • Vanneman, M. and G. Dranoff, Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer, 2012. 12(4): p. 237-51.
  • Turner, N.C. and J.S. Reis-Filho, Genetic heterogeneity and cancer drug resistance. Lancet Oncol, 2012. 13(4): p. e178-85.
  • Tredan, O., et al., Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst, 2007. 99(19): p. 1441-54.
  • Topalian, S.L., et al., Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol, 2014. 32(10): p. 1020-30.
  • Tirosh, I., et al., Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature, 2016. 539(7628): p. 309-313.
  • Tirosh, I., et al., Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science, 2016. 352(6282): p. 189-96.
  • Tezcan, O., et al., Targeting cellular and microenvironmental multidrug resistance. Expert Opin Drug Deliv, 2016. 13(9): p. 1199-202.
  • Tentler, J.J., et al., Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol, 2012. 9(6): p. 338-50.
  • Sweis, R.F., et al., Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res, 2016. 4(7): p. 563-8.
  • Stuelten, C.H., et al., Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J Cell Sci, 2005. 118(Pt 10): p. 2143-53.
  • Siefker-Radtke, A. and B. Curti, Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. Nat Rev Urol, 2018. 15(2): p. 112-124.
  • Shin, K., et al., Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors. Cancer Cell, 2014. 26(4): p. 521-33.
  • Shiga, K., et al., Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth. Cancers (Basel), 2015. 7(4): p. 2443-58.
  • Sharma, P., et al., Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell, 2017. 168(4): p. 707-723.
  • Shalek, A.K. and M. Benson, Single-cell analyses to tailor treatments. Sci Transl Med, 2017. 9(408).
  • Shackleton, M., et al., Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell, 2009. 138(5): p. 822-9.
  • Servais, C. and N. Erez, From sentinel cells to inflammatory culprits: cancerassociated fibroblasts in tumour-related inflammation. J Pathol, 2013. 229(2): p. 198-207.
  • Senthebane, D.A., et al., The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer. Int J Mol Sci, 2017. 18(7).
  • Saunders, N.A., et al., Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol Med, 2012. 4(8): p. 675-84.
  • Santi, A., F.G. Kugeratski, and S. Zanivan, Cancer Associated Fibroblasts: The Architects of Stroma Remodeling. Proteomics, 2018. 18(5-6): p. e1700167.
  • Sanchez-Laorden, B., et al., BRAF inhibitors induce metastasis in RAS mutant or inhibitorresistant melanoma cells by reactivating MEK and ERK signaling. Sci Signal, 2014. 7(318): p. ra30.
  • Ruffell, B., et al., Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell, 2014. 26(5): p. 623-37.
  • Rowinsky, E.K., Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors. J Clin Oncol, 2006. 24(19): p. 2981-4.
  • Rouanne, M., et al., Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. World J Urol, 2018.
  • Rosenberg, J.E., et al., Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, 2016. 387(10031): p. 1909-20.
  • Robinson, S.C., K.A. Scott, and F.R. Balkwill, Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha. Eur J Immunol, 2002. 32(2): p. 404-12.
  • Richardson, V.J., Divergent and synergistic regulation of matrix metalloprotease production by cytokines in combination with C-C chemokines. Int J Immunopathol Pharmacol, 2010. 23(3): p. 715-26.
  • Reis, S.T., et al., Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer. BMC Urol, 2012. 12: p. 18.
  • Ramsauer, M. and P.A. D'Amore, Contextual role for angiopoietins and TGFbeta1 in blood vessel stabilization. J Cell Sci, 2007. 120(Pt 10): p. 1810-7.
  • Rak, J., et al., Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res, 2000. 60(2): p. 490-8.
  • Rabold, K., et al., Cellular metabolism of tumor-associated macrophages - functional impact and consequences. FEBS Lett, 2017. 591(19): p. 3022-3041.
  • Quail, D.F. and J.A. Joyce, Microenvironmental regulation of tumor progression and metastasis. Nat Med, 2013. 19(11): p. 1423-37.
  • Qian, B.Z. and J.W. Pollard, Macrophage diversity enhances tumor progression and metastasis. Cell, 2010. 141(1): p. 39-51.
  • Pylayeva-Gupta, Y., E. Grabocka, and D. Bar-Sagi, RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer, 2011. 11(11): p. 761-74.
  • Powles, T., et al., MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 2014. 515(7528): p. 558-62.
  • Polanska, U.M. and A. Orimo, Carcinoma-associated fibroblasts: non-neoplastic tumourpromoting mesenchymal cells. J Cell Physiol, 2013. 228(8): p. 1651-7.
  • Pikarsky, E., et al., NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature, 2004. 431(7007): p. 461-6.
  • Paulsson, J. and P. Micke, Prognostic relevance of cancer-associated fibroblasts in human cancer. Semin Cancer Biol, 2014. 25: p. 61-8.
  • Pascal, L.E., et al., Differential Inductive Signaling of CD90 Prostate Cancer-Associated Fibroblasts Compared to Normal Tissue Stromal Mesenchyme Cells. Cancer Microenviron, 2011. 4(1): p. 51-9.
  • Pan, C.X., et al., Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. PLoS One, 2015. 10(8): p. e0134346.
  • Onita, T., et al., Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clin Cancer Res, 2002. 8(2): p. 471-80.
  • Ohlund, D., et al., Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med, 2017. 214(3): p. 579-596.
  • Ohaegbulam, K.C., et al., Human cancer immunotherapy with antibodies to the PD-1 and PDL1 pathway. Trends Mol Med, 2015. 21(1): p. 24-33.
  • Netea-Maier, R.T., J.W.A. Smit, and M.G. Netea, Metabolic changes in tumor cells and tumorassociated macrophages: A mutual relationship. Cancer Lett, 2018. 413: p. 102-109.
  • Navin, N.E., Cancer genomics: one cell at a time. Genome Biol, 2014. 15(8): p. 452.
  • Nakanishi, J., et al., Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother, 2007. 56(8): p. 1173-82.
  • Moisan, F., et al., Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers. Mol Oncol, 2014. 8(7): p. 1231-9.
  • Miyake, M., et al., Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1/2 and EGF pathways. Lab Invest, 2013. 93(7): p. 768-78.
  • Miyake, M., et al., CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer. Neoplasia, 2016. 18(10): p. 636-646.
  • Mirkin, B.L., et al., Identification of midkine as a mediator for intercellular transfer of drug resistance. Oncogene, 2005. 24(31): p. 4965-74.
  • Miller, M.A., et al., Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post- Translational Mechanism of Kinase Inhibitor Resistance. Cancer Discov, 2016. 6(4): p. 382-99.
  • Melchor, L., et al., Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia, 2014. 28(8): p. 1705-15.
  • Meads, M.B., R.A. Gatenby, and W.S. Dalton, Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer, 2009. 9(9): p. 665-74.
  • McGranahan, N. and C. Swanton, Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell, 2015. 27(1): p. 15-26.
  • McConkey, D.J., W. Choi, and C.P. Dinney, Genetic subtypes of invasive bladder cancer. Curr Opin Urol, 2015. 25(5): p. 449-58.
  • Mazur, A., et al., Cleavage of Type I Collagen by Fibroblast Activation Protein-alpha Enhances Class A Scavenger Receptor Mediated Macrophage Adhesion. PLoS One, 2016. 11(3): p. e0150287.
  • Macosko, E.Z., et al., Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. Cell, 2015. 161(5): p. 1202-1214.
  • Lubet, R.A., et al., Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations. Mol Cancer Ther, 2006. 5(4): p. 1073-8.
  • Lilli, C., et al., Effects of transforming growth factor-beta1 and tumour necrosis factor-alpha on cultured fibroblasts from skin fibroma as modulated by toremifene. Int J Cancer, 2002. 98(6): p. 824-32.
  • Li, J., L. Chen, and Z. Qin, Multifaceted tumor stromal fibroblasts. Cancer Microenviron, 2012. 5(3): p. 187-93.
  • Li, H. and R. Durbin, Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics, 2009. 25(14): p. 1754- 60.
  • Li, B. and C.N. Dewey, RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics, 2011. 12: p. 323.
  • Lee, M.J., et al., Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell, 2012. 149(4): p. 780-94.
  • Leber, T.M. and F.R. Balkwill, Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). Br J Cancer, 1998. 78(6): p. 724-32.
  • Le Novere, N., Quantitative and logic modelling of molecular and gene networks. Nat Rev Genet, 2015. 16(3): p. 146-58.
  • Kompier, L.C., et al., FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One, 2010. 5(11): p. e13821.
  • Komohara, Y., M. Jinushi, and M. Takeya, Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci, 2014. 105(1): p. 1-8.
  • Komohara, Y. and M. Takeya, CAFs and TAMs: maestros of the tumour microenvironment. J Pathol, 2017. 241(3): p. 313-315.
  • Knowles, M.A. and C.D. Hurst, Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer, 2015. 15(1): p. 25-41.
  • Knight, D.A., et al., Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest, 2013. 123(3): p. 1371-81.
  • Klijn, C., et al., A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol, 2015. 33(3): p. 306-12.
  • Klein, L., et al., Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see). Nat Rev Immunol, 2014. 14(6): p. 377-91.
  • Kim, K.T., et al., Single-cell mRNA sequencing identifies subclonal heterogeneity in anticancer drug responses of lung adenocarcinoma cells. Genome Biol, 2015. 16: p. 127.
  • Kim, K.T., et al., Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma. Genome Biol, 2016. 17: p. 80.
  • Kim, E., et al., Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy. PLoS Biol, 2018. 16(3): p. e2002930.
  • Kiessling, M.K., et al., Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget, 2015. 6(39): p. 42183-96.
  • Katerinaki, E., et al., TNF-alpha increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes. Br J Cancer, 2003. 89(6): p. 1123-9.
  • Kalluri, R. and M. Zeisberg, Fibroblasts in cancer. Nat Rev Cancer, 2006. 6(5): p. 392-401.
  • Jones, D.R., Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases. Br J Pharmacol, 2014. 171(12): p. 2925-39.
  • Jinushi, M. and Y. Komohara, Tumor-associated macrophages as an emerging target against tumors: Creating a new path from bench to bedside. Biochim Biophys Acta, 2015. 1855(2): p. 123-30.
  • Jebar, A.H., et al., FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene, 2005. 24(33): p. 5218-25.
  • Ikehara, S., et al., Functional T cells in athymic nude mice. Proc Natl Acad Sci U S A, 1984. 81(3): p. 886-8.
  • Huynh, P.T., et al., CD90(+) stromal cells are the major source of IL-6, which supports cancer stem-like cells and inflammation in colorectal cancer. Int J Cancer, 2016. 138(8): p. 1971-81.
  • Hurst, C.D. and M.A. Knowles, Molecular subtyping of invasive bladder cancer: time to divide and rule? Cancer Cell, 2014. 25(2): p. 135-6.
  • Hui, L. and Y. Chen, Tumor microenvironment: Sanctuary of the devil. Cancer Lett, 2015. 368(1): p. 7-13.
  • Herrera, M., et al., Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci, 2013. 104(4): p. 437-44.
  • He, F., et al., Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas. Cancer Res, 2015. 75(10): p. 2017-28.
  • Hashimoto, O., et al., Collaboration of cancer-associated fibroblasts and tumour-associated macrophages for neuroblastoma development. J Pathol, 2016. 240(2): p. 211-23.
  • Hanzelmann, S., R. Castelo, and J. Guinney, GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics, 2013. 14: p. 7.
  • Hagood, J.S., et al., Loss of fibroblast Thy-1 expression correlates with lung fibrogenesis. Am J Pathol, 2005. 167(2): p. 365-79.
  • Hagemann, T., et al., Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol, 2005. 175(2): p. 1197-205.
  • Haanen, J.B. and C. Robert, Immune Checkpoint Inhibitors. Prog Tumor Res, 2015. 42: p. 55- 66.
  • Gurusamy, D., et al., Novel "Elements" of Immune Suppression within the Tumor Microenvironment. Cancer Immunol Res, 2017. 5(6): p. 426-433.
  • Guo, G., et al., Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet, 2013. 45(12): p. 1459-63.
  • Gungor, C., et al., Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Cancer Res, 2011. 71(14): p. 5009-19.
  • Gui, Y., et al., Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet, 2011. 43(9): p. 875-8.
  • Grimm, S., et al., Malignancy of bladder cancer cells is enhanced by tumor-associated fibroblasts through a multifaceted cytokine-chemokine loop. Exp Cell Res, 2015. 335(1): p. 1- 11.
  • Giannoni, E., et al., Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. Antioxid Redox Signal, 2011. 14(12): p. 2361-71.
  • Gerlinger, M. and C. Swanton, How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer, 2010. 103(8): p. 1139-43.
  • Gascard, P. and T.D. Tlsty, Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev, 2016. 30(9): p. 1002-19.
  • Gao, Z., et al., Mitochondrial dynamics controls anti-tumour innate immunity by regulating CHIP-IRF1 axis stability. Nat Commun, 2017. 8(1): p. 1805.
  • Gal, P., et al., How Signaling Molecules Regulate Tumor Microenvironment: Parallels to Wound Repair. Molecules, 2017. 22(11).
  • Fisher, R., L. Pusztai, and C. Swanton, Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer, 2013. 108(3): p. 479-85.
  • Ferguson, D., et al., Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models. Clin Cancer Res, 2005. 11(8): p. 3045-54.
  • Fang, H. and Y.A. Declerck, Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res, 2013. 73(16): p. 4965-77.
  • Ebert, P.J.R., et al., MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. Immunity, 2016. 44(3): p. 609-621.
  • Duda, D.G., et al., Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A, 2010. 107(50): p. 21677-82.
  • Dobin, A., et al., STAR: ultrafast universal RNA-seq aligner. Bioinformatics, 2013. 29(1): p. 15-21.
  • Ding, L., et al., Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature, 2012. 481(7382): p. 506-10.
  • Deng, W.G., Y. Zhu, and K.K. Wu, Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation. J Biol Chem, 2003. 278(7): p. 4770-7.
  • DePristo, M.A., et al., A framework for variation discovery and genotyping using nextgeneration DNA sequencing data. Nat Genet, 2011. 43(5): p. 491-8.
  • Dadhania, V., et al., Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine, 2016. 12: p. 105-117.
  • Cooper, Z.A., et al., Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology, 2016. 5(3): p. e1136044.
  • Clark, P.E., et al., Bladder cancer. J Natl Compr Canc Netw, 2013. 11(4): p. 446-75.
  • Cibulskis, K., et al., Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol, 2013. 31(3): p. 213-9.
  • Chung, W., et al., Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat Commun, 2017. 8: p. 15081.
  • Choi, W., et al., Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol, 2014. 11(7): p. 400-10.
  • Choi, W., et al., Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell, 2014. 25(2): p. 152- 65.
  • Cheng, G.Z., et al., Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res, 2007. 67(5): p. 1979- 87.
  • Chen, W.J., et al., Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat Commun, 2014. 5: p. 3472.
  • Chang, P.H., et al., Activation of Robo1 signaling of breast cancer cells by Slit2 from stromal fibroblast restrains tumorigenesis via blocking PI3K/Akt/beta-catenin pathway. Cancer Res, 2012. 72(18): p. 4652-61.
  • Carthon, B.C., et al., Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res, 2010. 16(10): p. 2861-71.
  • Cairns, R., I. Papandreou, and N. Denko, Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res, 2006. 4(2): p. 61-70.
  • Buhrman, G., et al., Allosteric modulation of Ras positions Q61 for a direct role in catalysis. Proc Natl Acad Sci U S A, 2010. 107(11): p. 4931-6.
  • Boorjian, S.A., et al., T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res, 2008. 14(15): p. 4800-8.
  • Binnewies, M., et al., Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med, 2018. 24(5): p. 541-550.
  • Barker, T.H. and J.S. Hagood, Getting a grip on Thy-1 signaling. Biochim Biophys Acta, 2009. 1793(5): p. 921-3.
  • Baris, O., et al., Transcriptional profiling reveals coordinated up-regulation of oxidative metabolism genes in thyroid oncocytic tumors. J Clin Endocrinol Metab, 2004. 89(2): p. 994- 1005.
  • Balkwill, F., Tumour necrosis factor and cancer. Nat Rev Cancer, 2009. 9(5): p. 361-71.
  • Balar, A.V., et al., Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet, 2017. 389(10064): p. 67-76.
  • Bai, F., et al., Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. Cancer Immunol Immunother, 2012. 61(4): p. 523-33.
  • Avni, O., et al., T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nat Immunol, 2002. 3(7): p. 643-51.
  • Augsten, M., Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front Oncol, 2014. 4: p. 62.
  • Attieh, Y., et al., Cancer-associated fibroblasts lead tumor invasion through integrin-beta3- dependent fibronectin assembly. J Cell Biol, 2017. 216(11): p. 3509-3520.
  • Arnott, C.H., et al., Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene, 2004. 23(10): p. 1902-10.
  • Appels, N.M., J.H. Beijnen, and J.H. Schellens, Development of farnesyl transferase inhibitors: a review. Oncologist, 2005. 10(8): p. 565-78.
  • Anchang, B., et al., Visualization and cellular hierarchy inference of single-cell data using SPADE. Nat Protoc, 2016. 11(7): p. 1264-79.
  • Almendro, V., et al., Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep, 2014. 6(3): p. 514-27.
  • Almendro, V., A. Marusyk, and K. Polyak, Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol, 2013. 8: p. 277-302.
  • Alizadeh, A.A., et al., Toward understanding and exploiting tumor heterogeneity. Nat Med, 2015. 21(8): p. 846-53.
  • Aggen, D.H. and C.G. Drake, Biomarkers for immunotherapy in bladder cancer: a moving target. J Immunother Cancer, 2017. 5(1): p. 94.